Page last updated: 2024-10-22

albuterol and Late Onset Diseases

albuterol has been researched along with Late Onset Diseases in 1 studies

Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Koeberl, DD	1
Case, LE	1
Desai, A	1
Smith, EC	1
Walters, C	1
Han, SO	1
Thurberg, BL	1
Young, SP	1
Bali, D	1
Kishnani, PS	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Phase 1/2 Double-Blind Study of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy[NCT01885936]			Phase 1/Phase 2	16 participants (Actual)	Interventional	2013-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Adverse Events.

All participants who experienced adverse events. (NCT01885936)
Timeframe: 52 weeks

Intervention	Participants (Count of Participants)
Albuterol	5
Placebo Comparator	5

Change in 6 Minute Walk Test

The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. Assessed by physical therapist. (NCT01885936)
Timeframe: Baseline, Week 6, and Week 52

Intervention	meters (Mean)
	Change at 6 Weeks	Change at 52 Weeks
Albuterol	24.0	43.6
Placebo Comparator	32.0	13.6

Change in Forced Vital Capacity From Pulmonary Function Tests at 30 Weeks and 52 Weeks.

FVC (forced vital capacity) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. (NCT01885936)
Timeframe: Baseline, Week 30, and Week 52

Intervention	Percent of predicted FVC (Mean)
	Change at 30 Weeks	Change at 52 Weeks
Albuterol	-0.2	-1.3
Placebo Comparator	0.4	3.0

Trials

1 trial available for albuterol and Late Onset Diseases

Article	Year
Improved muscle function in a phase I/II clinical trial of albuterol in Pompe disease. Molecular genetics and metabolism, 2020, Volume: 129, Issue:2 Topics: Adult; Albuterol; Double-Blind Method; Enzyme Replacement Therapy; Female; Forced Expiratory Volume;	2020